Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 5;119(28):e2111003119. doi: 10.1073/pnas.2111003119

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 the Author(s). Published by PNAS.

This article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

PMC Copyright notice

Fig. 4. — Assessment of CT-2A tumor immune infiltrates after STING agonist treatment. (A) BILs profile of CT-2A tumors at days 3 and 7 using a typical gating procedure. Biologically independent animals per group (PBS, n = 3; ADU-S100, n = 4). P values calculated by two-way ANOVA. (B) PD-L1⁺ percentage of CD45⁻ cells. P value calculated by unpaired t test. (C) MDSC populations within the BILs. P values calculated by one-way ANOVA. (D) 2D t-SNE plots at day 3; treated mice in red and controls in dark gray. (E) t-SNE map for treated mice at day 3 colored by the FlowSOM populations; main up-regulated FlowSOM populations are highlighted. (F) Heatmap and hierarchical clustering of the FlowSOM populations at day 3.